Nathalie Dompé is an Italian pharmaceutical executive and the chief executive officer of Dompé Farmaceutici and Dompé Holdings. She plays a central role in the family-owned pharmaceutical group’s international business, particularly its operations in the United States. She is also known for her marriage to Silicon Valley investor Chamath Palihapitiya.
Born in Milan on December 26, 1986, Dompé is 39 years old as of October 21, 2026. Her professional background includes corporate social responsibility, technology investments, board-level governance and pharmaceutical business development. Her career within the Dompé group dates back to at least 2012, well before her marriage attracted wider public attention.
Key takeaways
- Current role: Nathalie Dompé serves as CEO of Dompé Farmaceutici and Dompé Holdings, according to the company’s executive directory checked in October 2026.
- Age and background: She was born on December 26, 1986, in Milan, Italy, as recorded in a 2017 corporate securities prospectus.
- Education and career: She graduated in Business Administration from Bocconi University and has held corporate responsibilities since at least 2012.
- Professional work: Her responsibilities include U.S. pharmaceutical market development, strategic partnerships and corporate governance.
- Marriage: She married investor and Social Capital founder Chamath Palihapitiya in Portofino, Italy, in July 2023.
Nathalie Dompé profile summary
| Field | Details |
|---|---|
| Full name | Nathalie Francesca Maria Dompé |
| Known as | Nathalie Dompé |
| Date of birth | December 26, 1986 |
| Age | 39, as of October 21, 2026 |
| Birthplace | Milan, Italy |
| Nationality | Italian |
| Profession | Pharmaceutical executive and business leader |
| Current position | CEO of Dompé Farmaceutici |
| Additional position | CEO of Dompé Holdings |
| Education | Business Administration, Bocconi University, Milan |
| Other professional involvement | Philogen and Movendo Technology |
| Father | Sergio Dompé |
| Husband | Chamath Palihapitiya |
| Marriage | July 2023, Portofino, Italy |
Early life, education and family background
Nathalie Francesca Maria Dompé was born in Milan into the family associated with Dompé Farmaceutici, an established Italian pharmaceutical company. Her father, Sergio Dompé, has held senior leadership positions within the business and is identified as Executive President in the company’s current management directory.
Her family background placed her close to the pharmaceutical industry, but her documented professional career developed through several different responsibilities before her current executive role.
Dompé studied Business Administration at Bocconi University in Milan, an institution known for its business and economics programmes. Her official company biography confirms the qualification, although it does not specify her graduation year.
Details of her early career appear in a 2017 B.F. Holding securities prospectus. The document identifies her full name, date of birth, education and several professional appointments.
That record provides a clearer picture of her career development than the brief executive biographies that usually accompany corporate announcements.
How Nathalie Dompé built her business career
Early responsibilities within the Dompé group
Nathalie’s documented involvement in the family business dates to at least 2012, when she held responsibilities relating to corporate social responsibility.
Corporate social responsibility concerns how a business manages its relationships with employees, communities and other stakeholders, as well as the social and environmental implications of its activities.
This work represents an identifiable early stage of her corporate career, rather than a retrospective assumption based on her later executive position.
By 2017, her professional responsibilities had expanded into technology-related business management and corporate governance.
Her appointment at rDNA in 2017
In January 2017, Dompé became managing director of rDNA, a company associated with investments in innovative technology projects.
The appointment is recorded in the B.F. Holding prospectus issued that year.
This position added a technology-investment dimension to her professional background. It also helps explain why later corporate descriptions associate her with opportunities involving both pharmaceuticals and high technology.
Her involvement with technology-related businesses extended to board positions. Historical records identify associations with companies including Movendo Technology and Philogen.
Those appointments established experience across different types of corporate activity, although the precise commercial results of her individual decisions are not detailed in the available records.
The January 2017 rDNA appointment is a historical fact and should not be taken to mean she continues to hold that particular position in 2026.
Leadership at Dompé Farmaceutici
Dompé subsequently became a senior executive within the pharmaceutical group.
Her official Dompé executive biography identifies her as chief executive officer of Dompé Farmaceutici and Dompé Holdings.
The two positions concern related but distinct parts of the family business.
Dompé Farmaceutici operates in pharmaceutical research, development and commercialization. Dompé Holdings is the family holding company associated with broader business interests, including pharmaceuticals and technology.
Her official responsibilities at Dompé Farmaceutici include oversight, market development and strategic approval of new medicines launched by the company in the United States.
She is also involved in identifying business opportunities and developing relationships with pharmaceutical and technology-sector leaders.
These duties concern the commercial and strategic side of the pharmaceutical industry, where scientific research, regulatory requirements, distribution and partnerships all affect whether a medicine can reach patients.
Some earlier professional profiles described Nathalie as co-CEO, while the company’s current management directory identifies her as CEO. The precise date of any formal change in title is not established.
Her role in Dompé’s expansion into the United States
One of the most significant parts of Nathalie Dompé’s professional work concerns the company’s activities in the American pharmaceutical market.
Developing a medicine and bringing it to market are separate processes. Scientific research must establish a potential treatment, clinical studies must evaluate it, regulators must decide whether it can be authorized, and the company must then organize its commercial availability.
Dompé’s American operations involve several of these stages, including research partnerships, regulatory processes and market development.
The significance of Oxervate
A major milestone for Dompé’s American pharmaceutical business came on August 22, 2018, when the U.S. Food and Drug Administration approved Oxervate, also known as cenegermin-bkbj.
The medicine was authorized for neurotrophic keratitis, a rare condition affecting the cornea in which damage to the nerves can interfere with normal healing.
The approval gave Dompé an authorized treatment in the United States for a rare eye disease.
It also provides useful context for Nathalie’s later public discussions of the challenges involved in launching and commercializing pharmaceutical products internationally.
The development and FDA approval of Oxervate were achievements of the company and its scientific teams. Nathalie’s documented contribution concerns executive and commercial responsibilities; she should not be described as the scientist who developed the medicine.
What she has said about the American market
In a November 6, 2023 interview with Alessandra Puato for Corriere della Sera, Nathalie discussed Dompé’s American operations and international business strategy.
She highlighted the concentration of research institutions, biotechnology companies and scientific expertise in the United States.
Her comments reflected an important distinction in the company’s international approach: maintaining pharmaceutical manufacturing in Italy while developing research relationships and commercial opportunities in the American market.
The interview also addressed company revenue, growth expectations and potential acquisitions. Those statements reflected Dompé’s business position and plans at the time, rather than guaranteed future results.
The underlying strategy helps explain Nathalie’s executive responsibilities. Her role connects an established Italian pharmaceutical business with the research, regulatory and commercial environment of the United States.
She also discussed leadership differences between Europe and America in a November 2022 Pharmaceutical Executive podcast episode. The interview covered her experience with rare-disease drug commercialization and the practical challenges facing pharmaceutical businesses across the two markets.
Together, these public discussions provide a more specific account of her work than her CEO title alone.
Board positions and professional recognition
Alongside her executive responsibilities, Nathalie Dompé has been involved in corporate governance through board appointments.
One of her documented positions is with Philogen, a biotechnology company focused on developing pharmaceutical treatments.
Philogen’s official board directory identifies her as a director and describes her professional background within the Dompé business group.
Her involvement with Movendo Technology also reflects experience in technology-related corporate activity, although these board associations should be distinguished from direct responsibility for the companies’ scientific developments.
The 2022 Women Corporate Directors award
On September 12, 2022, Dompé Farmaceutici received the Visionary Award for Leadership and Governance of a Private Company from Women Corporate Directors.
Nathalie accepted the award on behalf of the company.
The distinction matters because the formal recognition was awarded to Dompé Farmaceutici rather than to Nathalie personally.
The award nevertheless documents her public role in representing the business and its approach to corporate leadership.
Her combination of executive responsibilities and board-level positions reflects a career involving business administration, pharmaceutical commercialization and the governance of companies operating in related industries.
Nathalie Dompé and Chamath Palihapitiya
Nathalie Dompé is married to Chamath Palihapitiya, the venture capitalist and entrepreneur who founded Social Capital.
Palihapitiya is known for his earlier career at Facebook, his investments in technology companies and his involvement in the All-In podcast.
Their relationship brought Nathalie wider recognition among readers following Silicon Valley investors, although her own corporate career was established before their marriage.
Their wedding in July 2023
Nathalie and Chamath married in Portofino, a coastal town in Italy, in July 2023.
Italian newspaper Il Secolo XIX reported their wedding on July 25, 2023.
The marriage was also covered by Vanity Fair Italia.
A later U.S. government transcript, published in July 2025, identified Nathalie as Palihapitiya’s wife, providing a subsequent public reference to their relationship.
Their marriage connects two established business backgrounds: the Italian pharmaceutical industry and American venture capital.
It does not mean their professional investments, company responsibilities or assets should be treated as interchangeable.
Their family and public appearances
Vanity Fair Italia reported in July 2023 that the couple have two children together. Nathalie’s professional biography at Philogen also identifies her as a parent.
The children’s personal information is not necessary to understanding her public career.
Nathalie and Chamath have appeared together at public events, including the Breakthrough Prize ceremonies.
Getty Images documented their attendance at the 12th Breakthrough Prize Ceremony in Santa Monica, California, on April 18, 2026.
The couple also appeared together in a January 27, 2026 episode of The Katie Miller Podcast, titled Chamath & Nathalie on Leaving California, Tech Investments & Their Marriage.
The published episode description identifies their marriage and technology investments among its subjects. It offers a more recent public appearance by the couple, although the episode listing alone does not establish the details of their private relationship history.
What is Nathalie Dompé doing in 2026?
As of October 21, 2026, Dompé’s official management directory identifies Nathalie Dompé as CEO of Dompé Farmaceutici.
Her professional activities remain connected to the company’s international pharmaceutical operations.
During 2026, Dompé announced several developments in its clinical research programmes.
In March, the company announced that the first patient had been enrolled in a Phase 2 study investigating intranasal nerve growth factor for cerebral palsy.
In July, Dompé announced the first patient had been dosed in a Phase 3 study investigating cenegermin-bkbj for non-arteritic anterior ischemic optic neuropathy, commonly known as NAION.
These announcements concern investigational treatments. They establish clinical-study activity, not the success of the treatments or new regulatory approvals.
They also describe company research programmes rather than scientific work personally undertaken by Nathalie.
Her continued public role was illustrated on October 11, 2026, when Dompé reported that she delivered opening remarks at its Scientific Open House held during the American Academy of Ophthalmology meeting in New Orleans.
The event brought her executive responsibilities into a setting focused on ophthalmology and pharmaceutical research, two areas closely associated with Dompé’s American operations.
Her current position therefore follows a documented career spanning corporate responsibility, technology-related management, board governance and pharmaceutical commercialization. The October 2026 company directory confirms that she remains responsible for leading Dompé Farmaceutici, with a particular role in connecting the Italian business to its American market.
More from instantmag.co.uk.
